Last reviewed · How we verify
ALIMTA plus Epirubicin
Topoisomerase I inhibitor
Topoisomerase I inhibitor Used for Non-small cell lung cancer, Mesothelioma.
At a glance
| Generic name | ALIMTA plus Epirubicin |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | Antineoplastic agents |
| Target | Topoisomerase I, Topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Alimta (pemetrexed) works by inhibiting the enzyme topoisomerase I, which is involved in DNA replication and repair. Epirubicin is an anthracycline antibiotic that intercalates DNA and inhibits the enzyme topoisomerase II.
Approved indications
- Non-small cell lung cancer
- Mesothelioma
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALIMTA plus Epirubicin CI brief — competitive landscape report
- ALIMTA plus Epirubicin updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI